Tuesday, October 11, 2016

Mentholated Bronchial Balsam





1. Name Of The Medicinal Product



Mentholated Bronchial Balsam or Covonia Mentholated Cough Mixture or Superdrug Mentholated Bronchial Mixture or Gordons Chesty Cough Linctus.


2. Qualitative And Quantitative Composition










Menthol BP




4.0mg/5ml




Squill Tincture HSE




0.6ml/5ml




Liquorice Liquid Extract BP




0.125ml/5ml



3. Pharmaceutical Form



Mixture



4. Clinical Particulars



4.1 Therapeutic Indications



For the symptomatic relief of productive (chesty) coughs and sore throats.



4.2 Posology And Method Of Administration



Oral



Recommended doses



Adults, the elderly and children over 12 years: one or two 5ml spoonfuls.



Children 5 – 12 years: one 5ml spoonful.



Dosage schedule



The dose to be taken every four hours if required.



4.3 Contraindications



Contraindicated in patients with known hypersensitivity to any of the ingredients. Also contraindicated in patients with cardiac disorders.



4.4 Special Warnings And Precautions For Use



If symptoms persist or worsen consult your doctor.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Toxicity of squill glycosides may be increased when given in combination with thiazides or loop diuretics, as these may cause hypokalaemia and hypomagnesaemia which may lead to cardiac arrhythmias.



When used with carbenoxolone it may produce sodium and water retention and hypokalaemia, and may give rise to greater toxicity of squill.



4.6 Pregnancy And Lactation



There are no adverse reports when used in recommended doses. However, as with all medicines care should be taken when using this product in pregnancy and medical advice sought if necessary.



4.7 Effects On Ability To Drive And Use Machines



None



4.8 Undesirable Effects



No adverse effects have been reported with this product, however, a few cases of hypersensitivity reactions to menthol have been reported. These include generalised urticaria and flushing, menthol may give rise to contact dermatitis.



Liquorice may cause sodium and water retention, and hypokalaemia.



4.9 Overdose



Ingestion of large doses of the active ingredients has been reported to cause the following effects: gastrointestinal disturbances such as abdominal pain, nausea, vomiting and diarrhoea would be expected to occur with the menthol and squill. Common symptoms of digoxin overdosage include headache, facial pain, fatigue, weakness, dizziness, drowsiness, disorientation, mental confusion, bad dreams and more rarely delirium, acute psychoses, and hallucinations. Convulsions have been reported. Visual disturbances including blurred vision may occur. Colour vision may be affected with objects appearing yellow or less frequently green, red, brown, blue or white.



Adverse effects on the heart may result from the cardiac glycosides in squill. Toxic doses may cause or aggravate heart failure. Supraventricular or ventricular arrhythmias and defects of conduction are common and may be an early indication of excessive dosage.



In addition CNS effects such as vertigo, ataxia and drowsiness have been reported after ingestion of large quantities of menthol; reported adverse effects following excessive ingestion of liquorice include hypertension, congestive heart failure, cardiac arrest, headache, muscle weakness, myopathy, myoglobinuria, paralysis, hyperprolactinaemia and amenorrhoea. In the unlikely event of overdosage with this preparation, gastric lavage and / or symptomatic treatment together with supportive measures should be employed.



Treatment of acute digoxin poisoning consists of emptying the stomach by emesis or lavage. Activated charcoal may be given. Cardiac toxicity should be treated under ECG control and serum electrolytes should be monitored. Anti-arrhythmic treatment may be necessary and should be determined by the specific arrhythmia present. Atropine may be given intravenously to control bradycardia and in patients with heart block; cardiac pacing may be necessary if atropine is not effective. Cholestyramine or colestipol may be of use in increasing the elimination of cardiac glycosides.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Menthol dilates the blood vessels causing a sensation of coldness followed by analgesic effect. It is used to relieve the symptoms of bronchitis, sinusitis and similar conditions.



Squill has an irritant effect on the gastric mucosa, it has a reflex expectorant action.



Liquorice is a demulcent and mild expectorant.



5.2 Pharmacokinetic Properties



After absorption menthol is excreted in the bile and urine as a glucuronide.



Squill glycosides are poorly absorbed from the gastro-intestinal tract, they are of short acting duration and are not cumulative; they are excreted in the urine and faeces.



No information is available on the pharmacokinetics of liquorice.



5.3 Preclinical Safety Data



None



6. Pharmaceutical Particulars



6.1 List Of Excipients



Peppermint oil BP, anise oil BP, capsicum tincture BPC, syrup BP, liquid glucose BPC 1963, veegum k, sodium nipasept, glycerol BP, caramel BPC and purified water BP.



6.2 Incompatibilities



None known



6.3 Shelf Life



150ml: 36 months unopened



200ml: 36 months unopened



6.4 Special Precautions For Storage



Store below 25°C



6.5 Nature And Contents Of Container



150ml: amber glass bottle with plastic cap with EPE/Saranex liner or white plastic child resistant cap with EPE/Saranex liner or white 28mm cap with tamper evident band and EPE Saranex liner or white 28mm Child-resistant cap with Tamper Evident band and EPE/Saranex Liner



200ml: amber glass bottle with plastic cap with EPE/Saranex liner or white plastic child resistant cap with EPE/Saranex liner or white 28mm cap with tamper evident band and EPE Saranex liner or white 28mm Child-resistant cap with Tamper Evident band and EPE/Saranex Liner



6.6 Special Precautions For Disposal And Other Handling



None



7. Marketing Authorisation Holder



L.C.M. Ltd.,



Linthwaite Laboratories



Huddersfield



HD7 5QH



8. Marketing Authorisation Number(S)



PL 12965/0026



9. Date Of First Authorisation/Renewal Of The Authorisation



24.03.94 / 13.04.99



10. Date Of Revision Of The Text



August 2004



11 DOSIMETRY


Not Applicable



12 INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS


Not Applicable




Plendil


Generic Name: felodipine (fe LOE di peen)

Brand Names: Plendil


What is felodipine?

Felodipine is in a group of drugs called calcium channel blockers. It works by relaxing the muscles of your heart and blood vessels.


Felodipine is used to treat hypertension (high blood pressure).


Felodipine may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about felodipine?


You should not use felodipine if you are allergic to it.

Before taking felodipine, tell your doctor if you have liver disease or congestive heart failure.


Many drugs can interact with felodipine. Tell your doctor about all other medications you use.


Your blood pressure will need to be checked often and you may need other blood tests at your doctor's office. Visit your doctor regularly.


Keep using this medicine as directed, even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medication for the rest of your life.


Brush and floss your teeth regularly while taking this medication. Felodipine can cause mild swelling of your gums, which may be avoided with good dental hygiene.


What should I discuss with my healthcare provider before taking felodipine?


You should not use felodipine if you are allergic to it.

If you have any of these other conditions, you may need a dose adjustment or special tests:


  • liver disease; or


  • congestive heart failure.




FDA pregnancy category C. It is not known whether felodipine will harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant while using this medication.. It is not known whether felodipine passes into breast milk or if it could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I take felodipine?


Take exactly as prescribed by your doctor. Do not take in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.


Your doctor may occasionally change your dose to make sure you get the best results.


You make felodipine without food or a light meal, but take it the same way each time.


Do not crush, chew, or break an extended-release tablet. Swallow it whole. Breaking the pill may cause too much of the drug to be released at one time. Call your doctor if you have ongoing vomiting or diarrhea, or if you are sweating more than usual. These conditions can lead to severely low blood pressure.

Your blood pressure will need to be checked often and you may need other blood tests at your doctor's office. Visit your doctor regularly.


Keep using this medicine as directed, even if you feel well. High blood pressure often has no symptoms. You may need to use blood pressure medication for the rest of your life.


Brush and floss your teeth regularly while taking this medication. Felodipine can cause mild swelling of your gums, which may be avoided with good dental hygiene.


Store at room temperature away from moisture, heat, and light.

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include severe dizziness, slow heart rate, redness or tingling in your arms and legs, and feeling like you might pass out.


What should I avoid while taking felodipine?


Grapefruit and grapefruit juice may interact with felodipine and lead to potentially dangerous effects. Discuss the use of grapefruit products with your doctor. Do not increase or decrease the amount of grapefruit products in your diet without first talking to your doctor.


Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Get up slowly and steady yourself to prevent a fall. Drinking alcohol can lower your blood pressure further and may increase certain side effects of felodipine.

Felodipine side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as:

  • feeling like you might pass out;




  • feeling short of breath, swelling in your hands or feet;




  • fast or pounding heartbeats;




  • numbness or tingly feeling; or




  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling.



Less serious side effects may include:



  • headache, dizziness, drowsiness, weakness;




  • feeling restless or nervous;




  • nausea, upset stomach, constipation, diarrhea, stomach pain;




  • sleep problems (insomnia);




  • joint pain or muscle cramps;




  • warmth, redness, or tingly feeling under your skin;




  • mild rash;




  • urinating more than usual; or




  • cold symptoms such as stuffy nose, sneezing, sore throat.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect felodipine?


Tell your doctor about all other medicines you use, especially:



  • cimetidine (Tagamet);




  • conivaptan (Vaprisol);




  • imatinib (Gleevec);




  • isoniazid (for treating tuberculosis);




  • tacrolimus (Prograf);




  • an antibiotic such as clarithromycin (Biaxin), dalfopristin/quinupristin (Synercid), erythromycin (E.E.S., EryPed, Ery-Tab, Erythrocin), or telithromycin (Ketek);




  • antifungal medication such as clotrimazole (Mycelex Troche), itraconazole (Sporanox), ketoconazole (Nizoral), or voriconazole (Vfend);




  • an antidepressant such as nefazodone;




  • a beta-blocker such as atenolol (Tenormin, Tenoretic), carvedilol (Coreg), labetalol (Normodyne, Trandate), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), timolol (Blocadren), and others;




  • HIV/AIDS medicine such as atazanavir (Reyataz), delavirdine (Rescriptor), fosamprenavir (Lexiva), indinavir (Crixivan), nelfinavir (Viracept), saquinavir (Invirase), or ritonavir (Norvir);




  • other heart or blood pressure medications such as diltiazem (Cartia, Cardizem), nifedipine (Nifedical, Procardia), verapamil (Calan, Covera, Isoptin, Verelan), and others; or




  • seizure medication such as carbamazepine (Carbatrol, Tegretol), phenobarbital (Solfoton), or phenytoin (Dilantin).



This list is not complete and other drugs may interact with felodipine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Plendil resources


  • Plendil Side Effects (in more detail)
  • Plendil Use in Pregnancy & Breastfeeding
  • Drug Images
  • Plendil Drug Interactions
  • Plendil Support Group
  • 1 Review for Plendil - Add your own review/rating


  • Plendil Prescribing Information (FDA)

  • Plendil Consumer Overview

  • Plendil Monograph (AHFS DI)

  • Plendil Advanced Consumer (Micromedex) - Includes Dosage Information

  • Plendil MedFacts Consumer Leaflet (Wolters Kluwer)

  • Felodipine Professional Patient Advice (Wolters Kluwer)

  • Felodipine Prescribing Information (FDA)



Compare Plendil with other medications


  • Angina Pectoris Prophylaxis
  • High Blood Pressure
  • Raynaud's Syndrome


Where can I get more information?


  • Your pharmacist can provide more information about felodipine.

See also: Plendil side effects (in more detail)


Prudoxin



doxepin hydrochloride

Dosage Form: cream
Prudoxin™ (doxepin hydrochloride) Cream, 5%

FOR TOPICAL DERMATOLOGIC USE ONLY — NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE.



DESCRIPTION


Prudoxin (doxepin hydrochloride) Cream, 5% is a topical cream. Each gram contains: 50 mg of doxepin hydrochloride (equivalent to 44.3 mg of doxepin).


Doxepin hydrochloride is one of a class of agents known as dibenzoxepin tricyclic antidepressant compounds. It is an isomeric mixture of N,N-dimethyldibenz[b,e]oxepin-Δ11(6H),γ-propylamine hydrochloride. Doxepin hydrochloride has an empirical formula of C19H21NO•HCl and a molecular weight of 316.



Prudoxin Cream also contains sorbitol, cetyl alcohol, isopropyl myristate, glyceryl stearate, PEG-100 stearate, petrolatum, benzyl alcohol, titanium dioxide and purified water.



CLINICAL PHARMACOLOGY


Although doxepin HCl does have H1 and H2 histamine receptor blocking actions, the exact mechanism by which doxepin exerts its antipruritic effect is unknown. Prudoxin Cream can produce drowsiness which may reduce awareness, including awareness of pruritic symptoms. In 19 pruritic eczema patients treated with Prudoxin Cream, plasma doxepin concentrations ranged from nondetectable to 47 ng/mL from percutaneous absorption. Plasma levels from topical application of Prudoxin Cream can result in CNS and other systemic side effects.


Once absorbed into the systemic circulation, doxepin undergoes hepatic metabolism that results in conversion to pharmacologically-active desmethyldoxepin. Further glucuronidation results in urinary excretion of the parent drug and its metabolites. Desmethyldoxepin has a half-life that ranges from 28 to 52 hours and is not affected by multiple dosing. Plasma levels of both doxepin and desmethyldoxepin are highly variable and are poorly correlated with dosage. Wide distribution occurs in body tissues including lungs, heart, brain, and liver. Renal disease, genetic factors, age, and other medications affect the metabolism and subsequent elimination of doxepin. (See PRECAUTIONS - Drug Interactions.)



INDICATIONS AND USAGE


Prudoxin Cream is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus. (See DOSAGE AND ADMINISTRATION.)



CONTRAINDICATIONS


Because doxepin HCl has an anticholinergic effect and because significant plasma levels of doxepin are detectable after topical Prudoxin Cream application, the use of Prudoxin Cream is contraindicated in patients with untreated narrow angle glaucoma or a tendency to urinary retention.


Prudoxin Cream is contraindicated in individuals who have shown previous sensitivity to any of its components.



WARNINGS


Drowsiness occurs in over 20% of patients treated with Prudoxin Cream, especially in patients receiving treatment to greater than 10% of their body surface area. Patients should be warned about the possibility of sedation and cautioned against driving a motor vehicle or operating hazardous machinery while being treated with Prudoxin Cream.


The sedating effects of alcoholic beverages, antihistamines, and other CNS depressants may be potentiated when Prudoxin Cream is used.


If excessive drowsiness occurs it may be necessary to reduce the frequency of applications, the amount of cream applied, and/or the percentage of body surface area treated, or discontinue the drug. However, the efficacy with reduced frequency of applications has not been established.


Keep this product away from the eyes.



PRECAUTIONS


General Drowsiness: Since drowsiness may occur with the use of Prudoxin Cream, patients should be warned of the possibility and cautioned against driving a car or operating dangerous machinery while using this drug. Patients should also be cautioned that their response to alcohol may be potentiated.


Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be observed closely for confusion and oversedation when started on Prudoxin Cream. (See PRECAUTIONS - Geriatric Use.)


Use under occlusion: Occlusive dressings may increase the absorption of most topical drugs; therefore, occlusive dressings should not be utilized with Prudoxin Cream.


Contact sensitization: Use of Prudoxin Cream can cause Type IV hypersensitivity reactions (contact sensitization) to doxepin.



Drug Interactions


Studies have not been performed examining drug interactions with Prudoxin Cream. However, since plasma levels of doxepin following topical application of Prudoxin Cream can reach levels obtained with oral doxepin HCl therapy, the following drug interactions are possible following topical Prudoxin Cream application:


Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).


In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).


Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.


MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors. Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with Prudoxin Cream. The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage involved.


Cimetidine: Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated. Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.


Alcohol: Alcohol ingestion may exacerbate the potential sedative effects of Prudoxin Cream. This is especially important in patients who may use alcohol excessively.


Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of oral doxepin (75 mg/day).



Carcinogenesis, Mutagenesis, Impairment of Fertility


Carcinogenesis, mutagenesis, and impairment of fertility studies have not been conducted with doxepin hydrochloride.


Pregnancy Category B: Reproduction studies have been performed in which doxepin was orally administered to rats and rabbits at doses up to 0.6 and 1.2 times, respectively, the estimated exposure to doxepin that results from use of 16 grams of Prudoxin Cream per day (four applications of four grams of cream per day; dose multiples reflect comparisons made following normalization of the data on the basis of body surface area estimates) and have revealed no evidence of harm to rat or rabbit fetuses due to doxepin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.



Nursing Mothers


Doxepin is excreted in human milk after oral administration. It is possible that doxepin may also be excreted in human milk following topical application of Prudoxin Cream.


One case has been reported of apnea and drowsiness in a nursing infant whose mother was taking an oral dosage form of doxepin HCl.


Because of the potential for serious adverse reactions in nursing infants from doxepin, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.



Pediatric Use


The use of Prudoxin Cream in pediatric patients is not recommended. Safe conditions for use of Prudoxin Cream in children have not been established. One case has been reported of a 2.5 year old child who developed somnolence, grand mal seizure, respiratory depression, ECG abnormalities, and coma after treatment with Prudoxin Cream. A total of 27 grams had been applied over three days for eczema. He was treated with supportive care, activated charcoal, and systemic alkalization and recovered.



Geriatric Use


Clinical studies of Prudoxin Cream did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.


The extent of renal excretion of doxepin has not been determined. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selections.


Sedating drugs may cause confusion and oversedation in the elderly; elderly patients generally should be observed closely for confusion and oversedation when started on Prudoxin Cream. (See WARNINGS.)  An 80-year old male nursing home patient developed probable systemic anticholinergic toxicity which included urinary retention and delirium after Prudoxin Cream had been applied to his arms, legs and back three times daily for two days.



ADVERSE REACTIONS



Controlled Clinical Trials


Systemic Adverse Effects: In controlled clinical trials of patients treated with Prudoxin Cream, the most common systemic adverse event reported was drowsiness. Drowsiness occurred in 71 of 330 (22%) of patients treated with Prudoxin Cream compared to 7 of 334 (2%) of patients treated with vehicle cream. Drowsiness resulted in the premature discontinuation of the drug in approximately 5% of patients treated with Prudoxin Cream in controlled clinical trials.


Local Site Adverse Effects: In controlled clinical trials of patients treated with Prudoxin Cream, the most common local site adverse event reported was burning and/or stinging at the site of application. These occurred in 76 of 330 (23%) of patients treated with Prudoxin Cream compared to 54 of 334 (16%) of patients treated with vehicle cream. Most of these reactions were categorized as "mild"; however, approximately 25% of patients who reported burning and/or stinging reported the reaction as "severe". Four patients treated with Prudoxin Cream withdrew from the study because of the burning and/or stinging.


The table below presents the adverse events reported at an incidence of ≥ 1 % in either Prudoxin or vehicle cream treatment groups during the trials:














































Adverse EventPrudoxin

N=330
Vehicle

N=334
1Includes reports of “dry lips”, “dry throat”, and “thirst”
2Includes reports of “pruritus exacerbated”
3Includes report of “increased irritation at application site”
4Includes reports of “lightheadedness” and “dizziness/vertigo”
5Includes reports of “bitter taste” and “metallic taste in mouth”
Burning /Stinging76 (23.0%)54 (16.2%)
Drowsiness71 (21.5%)7 (2.1%)
Dry Mouth132 (9.7%)4 (1.2%)
Pruritus213 (3.9%)20 (6.0%)
Fatigue/Tiredness10 (3.0%)5 (1.5%)
Exacerbated Eczema10 (3.0%)8 (2.4%)
Other Application Site Reaction310 (3.0%)16 (4.8%)
Dizziness47 (2.1%)3 (0.9%)
Mental/Emotional Changes6 (1.8%)1 (0.3%)
Taste Perversion55 (1.5%)1 (0.3%)
Edema4 (1.2%)1 (0.3%)
Headache3 (0.9%)14 (4.2%)

Adverse events occurring in 0.5% to < 1.0% of Prudoxin Cream treated patients in the controlled clinical trials included: nervousness/anxiety, tongue numbness, fever, and nausea.



Post Marketing Experience


Twenty-six cases of allergic contact dermatitis have been reported in patients using Prudoxin Cream, twenty of which were documented by positive patch test to doxepin 5% cream.



OVERDOSAGE


Deaths may occur from overdosage with this class of drugs. As the management is complex and changing, it is recommended that the physician contact a poison control center for current information on treatment. Signs and symptoms of toxicity develop rapidly after tricyclic antidepressant overdose; therefore, hospital monitoring is required as soon as possible.



Manifestations


Should overdosage with topical application of Prudoxin Cream occur, the signs and symptoms may include: cardiac dysrhythmias, severe hypotension, convulsions, and CNS depression, including coma. Changes in the electrocardiogram, particularly in QRS axis or width, are clinically significant indicators of tricyclic antidepressant toxicity.


Other signs of overdose may include: confusion, disturbed concentration, transient visual hallucinations, dilated pupils, agitation, hyperactive reflexes, stupor, drowsiness, muscle rigidity, vomiting, hypothermia, hyperpyrexia, or any of the symptoms listed under ADVERSE REACTIONS.



General Recommendations


General: Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is strongly advised. If signs of toxicity occur at any time during this period, extended monitoring is recommended. There are case reports of patients succumbing to fatal dysrhythmias late after overdose; these patients had clinical evidence of significant poisoning prior to death and most received inadequate gastrointestinal decontamination. Monitoring of plasma drug levels should not guide management of the patient.


Cardiovascular: A maximal limb-lead QRS duration of >/=0.10 seconds may be the best indication of the severity of the overdose. Intravenous sodium bicarbonate should be used to maintain the serum pH in the range of 7.45 to 7.55. If the pH response is inadequate, hyperventilation may also be used. Concomitant use of hyperventilation and sodium bicarbonate should be done with extreme caution, with frequent pH monitoring. A pH>7.60 or a pCO2 <20 mm Hg is undesirable. Dysrhythmias unresponsive to sodium bicarbonate therapy/hyperventilation may respond to lidocaine, bretylium or phenytoin. Type 1A and 1C antiarrhythmics are generally contraindicated (e.g., quinidine, disopyramide, and procainamide).


In rare instances, hemoperfusion may be beneficial in acute refractory cardiovascular instability in patients with acute toxicity. However, hemodialysis, peritoneal dialysis, exchange transfusions, and forced diuresis generally have been reported as ineffective in tricyclic antidepressant poisoning.


CNS: In patients with CNS depression, early intubation is advised because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines, or if these are ineffective, other anticonvulsants (e.g., phenobarbital, phenytoin). Physostigmine is not recommended except to treat life-threatening symptoms that have been unresponsive to other therapies, and then only in consultation with a poison control center.


Pediatric Management: The principles of management of child and adult overdosages are similar. It is strongly recommended that the physician contact the local poison control center for specific pediatric treatment.



DOSAGE AND ADMINISTRATION


A thin film of Prudoxin Cream should be applied four times each day with at least a 3 to 4 hour interval between applications. There are no data to establish the safety and effectiveness of Prudoxin Cream when used for greater than 8 days. Chronic use beyond eight days may result in higher systemic levels and should be avoided. Use of Prudoxin Cream for longer than 8 days may result in an increased likelihood of contact sensitization.


The risk for sedation may increase with greater body surface area application of Prudoxin Cream (See WARNINGS section). Clinical experience has shown that drowsiness is significantly more common in patients applying Prudoxin Cream to over 10% of body surface area; therefore, patients with greater than 10% of body surface area (see WARNINGS section) affected should be particularly cautioned concerning possible drowsiness and other systemic adverse effects of doxepin. If excessive drowsiness occurs, it may be necessary to do one or more of the following: reduce the body surface area treated, reduce the number of applications per day, reduce the amount of cream applied, or discontinue the drug.


Occlusive dressings may increase the absorption of most topical drugs; therefore, occlusive dressings should not be utilized with Prudoxin Cream.


Rx Only.



HOW SUPPLIED


Prudoxin Cream is available in a 45 g (NDC 0064-3600-45) tube. Store at or below 27° C (80° F).


Distributed by:

Healthpoint, Ltd.

San Antonio, Texas 78215

1-800-441-8227

www.healthpoint.com


Manufactured by:

DPT Laboratories, Ltd.

San Antonio, Texas 78215


127932-0203



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL










Prudoxin 
doxepin hydrochloride  cream










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0064-3600
Route of AdministrationTOPICALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
DOXEPIN HYDROCHLORIDE (DOXEPIN)DOXEPIN HYDROCHLORIDE50 mg  in 1 g






















Inactive Ingredients
Ingredient NameStrength
SORBITOL 
CETYL ALCOHOL 
ISOPROPYL MYRISTATE 
GLYCERYL MONOSTEARATE 
POLYOXYL 100 STEARATE 
PETROLATUM 
BENZYL ALCOHOL 
TITANIUM DIOXIDE 
WATER 


















Product Characteristics
ColorWHITEScore    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
10064-3600-4545 g In 1 TUBENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDANDA02012610/01/2001


Labeler - HEALTHPOINT, LTD (965634504)









Establishment
NameAddressID/FEIOperations
DPT LABORATORIES, LTD832224526MANUFACTURE
Revised: 08/2010HEALTHPOINT, LTD

More Prudoxin resources


  • Prudoxin Side Effects (in more detail)
  • Prudoxin Use in Pregnancy & Breastfeeding
  • Prudoxin Drug Interactions
  • Prudoxin Support Group
  • 0 Reviews for Prudoxin - Add your own review/rating


  • Prudoxin Topical Advanced Consumer (Micromedex) - Includes Dosage Information

  • Zonalon Cream MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Prudoxin with other medications


  • Atopic Dermatitis
  • Dermatitis
  • Eczema
  • Lichen Simplex Chronicus
  • Pruritus

Monday, October 10, 2016

Simvastatine PCH




Simvastatine PCH may be available in the countries listed below.


Ingredient matches for Simvastatine PCH



Simvastatin

Simvastatin is reported as an ingredient of Simvastatine PCH in the following countries:


  • Netherlands

International Drug Name Search

Protopic topical


Generic Name: Tacrolimus topical
Class: Skin and Mucous Membrane Agents, Miscellaneous
Chemical Name: [3S - [3R*[E(1S*,3S*,4S*)],4S*,5R*,8S*,9E,12R*,14R*,15S*,16R*,18S*,19S*,26aR*]] - 5,6,8,11,12,13,14,15,16,17,18,19,24,25,26,26a - hexadecahydro - 5,19 - dihydroxy - 3 - [2 - (4 - hydroxy - 3 - methoxycyclohexyl) - 1 - methylethenyl] - 14,16 - dimethoxy - 4,10,12,18 - tetramethyl - 8 - (2 - propenyl) - 15,19 - epoxy - 3H - pyrido[2,1 - c][1,4]oxaazacyclotricosine - 1,7,20,21(4H,23H) - tetrone, monohydrate
CAS Number: 109581-93-3



  • Long-term safety of topical tacrolimus not established.a c




  • Malignancies (e.g., skin cancers, lymphoma) reported rarely in patients treated with topical calcineurin inhibitors, including tacrolimus; causal relationship not established.a c




  • Avoid continuous long-term use of topical tacrolimus; limit application to areas affected by atopic dermatitis.a c (See Carcinogenicity under Cautions.)




  • Topical tacrolimus is not indicated for use in children <2 years of age; only the 0.03% ointment is indicated for use in children 2–15 years of age.a c




Introduction

Immunosuppressive agent; macrolide produced by Streptomyces tsukubaensis.1


Uses for Protopic


Atopic Dermatitis


Second-line therapy for short-term and noncontinuous chronic treatment of moderate to severe atopic dermatitis (eczema) in immunocompetent adults and children 2–15 years of age who are unable to tolerate or have not responded to first-line therapies or for whom first-line therapies are inadvisable.4 6 7 8 13 14 a (See Carcinogenicity under Cautions.)


Not indicated for use in children <2 years of age.a c


Protopic Dosage and Administration


Administration


Topical Administration


Apply topically to the skin as a 0.03 or 0.l% ointment.a


For external use only; do not use in the eyes or ingest.a


Apply in thin layers;1 rub gently and completely into affected areas of skin.1


Use minimum amount required to control symptoms;12 a b limit application to areas affected with atopic dermatitis.a b (See Carcinogenicity under Cautions.)


Use with caution on the face or neck, large areas of the body (i.e., >50% of the total body surface area), or areas of broken skin.3 11 (See Absorption under Pharmacokinetics.)


Do not use occlusive dressings or wrappings.1 9


Dosage


Pediatric Patients


Atopic Dermatitis

Topical

Children 2–15 years of age: Apply 0.03% ointment to affected areas twice daily,1 9 approximately 12 hours apart.9


Adolescents ≥16 years of age: Apply 0.03 or 0.l% ointment to affected areas twice daily,1 9 b approximately 12 hours apart.9


Discontinue treatment following resolution of signs and symptoms (e.g., pruritus, rash, erythema).a b If manifestations persist beyond 6 weeks, reexamine patient and confirm diagnosis.a


Adults


Atopic Dermatitis

Topical

Apply 0.03 or 0.l% ointment to affected areas twice daily,1 9 approximately 12 hours apart.9


Discontinue treatment following resolution of signs and symptoms (e.g., pruritus, rash, erythema).a b If manifestations persist beyond 6 weeks, reexamine patient and confirm diagnosis.a


Prescribing Limits


Pediatric Patients


Atopic Dermatitis

Topical

For short-term and intermittent use only; avoid continuous long-term use.12 a Safety of noncontinuous use for >1 year not established.12 a c (See Carcinogenicity under Cautions.)


Adults


Atopic Dermatitis

Topical

For short-term and intermittent use only; avoid continuous long-term use.12 a Safety of noncontinuous use for >1 year not established.12 a c (See Carcinogenicity under Cautions.)


Special Populations


Hepatic Impairment


No dosage adjustment appears necessary; effect of hepatic impairment on the pharmacokinetics of topical tacrolimus has not been evaluated.a


Renal Impairment


No dosage adjustment appears necessary.a Effect of renal impairment on the pharmacokinetics of topical tacrolimus has not been evaluated;a following IV administration of tacrolimus, elimination in patients with renal dysfunction is similar to that in healthy individuals.a


Cautions for Protopic


Contraindications



  • Known hypersensitivity to tacrolimus or any ingredient in the formulation.1



Warnings/Precautions


Warnings


Carcinogenicity

Possible increased risk of malignancies.12 13 14 a (See Boxed Warning.)


Malignancies (including lymphoma and skin cancers) reported rarely in children and adults receiving topical tacrolimus.12 13 14 a Concerns also based on case reports of malignancies (including lymphoma and skin cancers) in patients (including transplant patients) receiving prolonged systemic therapy with calcineurin inhibitors (e.g., cyclosporine, tacrolimus);a animal studies indicating dose-related increases in the risk of lymphoma and other malignancies (particularly of the skin) with tacrolimus and other calcineurin inhibitors, possibly due to immunosuppression;1 10 11 12 13 14 a and known pharmacologic effects of these immunosuppressants.a 12 13 14


Systemic administration of tacrolimus in kidney and liver transplant patients is associated with development of lymphoma and skin cancers.13 14 a Risk appears to be related to dose and duration of exposure.13 14


Tacrolimus may be absorbed into systemic circulation following topical application, but concentrations generally are very low.14 a The lowest blood tacrolimus concentration associated with systemic effects (e.g., immunosuppression) has not been determined.a (See Absorption under Pharmacokinetics.)


Risk associated with systemic therapy is related to intensity and duration of immunosuppression.a The potential for systemic immunosuppression with topical tacrolimus and the drug’s role in the development of malignancies in humans have not been established.12 13 14 a Long-term studies in humans are needed to determine whether topical tacrolimus is associated with an increased risk of malignancies.12 13 Until such data are available, FDA recommends limiting use to the labeled indication, reserving the drug for use as a second-line agent for short-term and intermittent treatment.12 13 (See Atopic Dermatitis under Uses, see Immunocompromised Patients under Cautions, and see Dosage and Administration.) Carefully evaluate potential risks and benefits of therapy.12 13


Avoid use for malignant or premalignant skin conditions (e.g., cutaneous T-cell lymphoma [CTCL]), which may appear clinically similar to dermatitis.a


General Precautions


Lymphadenopathy

Lymphadenopathy reported; usually related to infections and resolves following appropriate anti-infective therapy.1 Also reported in association with malignancy.14 Investigate etiology if lymphadenopathy develops.1 Discontinue tacrolimus in the absence of a clear etiology or in the presence of acute infectious mononucleosis.a Monitor patients with lymphadenopathy to ensure that it resolves.1


Netherton’s Syndrome

Not recommended for use in patients with Netherton’s syndrome because of the potential for increased systemic absorption of tacrolimus.1


Generalized Erythroderma

Safety in patients with generalized erythroderma has not been established.1


Dermatologic Reactions

Possible burning sensation (burning, stinging, soreness) or pruritus at the treatment site within the first few days of initiating therapy.1 Reactions usually improve as the lesions of atopic dermatitis resolve.1


Infectious Complications

Clinical infections (e.g., bacterial, viral) at treatment sites should be cleared before initiating tacrolimus therapy.1 a Safety and efficacy not established for treatment of clinically infected atopic dermatitis.1


Possible increased risk of varicella-zoster infections (chickenpox or shingles), herpes simplex virus infection, or eczema herpeticum.1


Systemic administration of tacrolimus in kidney and liver transplant patients associated with increased susceptibility to infection.14


Phototoxicity

Although phototoxicity not reported in humans, it may be prudent to minimize or avoid natural or artificial sunlight exposure during tacrolimus therapy (including periods when no drug is on skin).1 Potential effects on skin response to ultraviolet (UV) damage are not known.a


Animal photocarcinogenicity studies indicate shortened time to skin tumor formation following chronic topical tacrolimus dosing with concurrent UV radiation exposure.1


Immunocompromised Patients

Safety and efficacy not established and not recommended for use in immunocompromised adults or children.12 13 14 a


Renal Effects

Acute renal failure reported rarely in patients receiving topical tacrolimus.a Increased risk of systemic absorption in patients with epidermal barrier defects, especially following topical application to large body surface areas.a


Use with caution in patients predisposed to renal impairment.a


Specific Populations


Pregnancy

Category C.1


Lactation

Not known whether distributed into milk following topical administration.11 Discontinue nursing or the drug.1


Blacks

0.03% ointment is ineffective; use the 0.1% ointment.1 4 11


Pediatric Use

Safety and efficacy not established and not recommended for use in children <2 years of age.1 a c


Use only the 0.03% ointment when topical tacrolimus is indicated in immunocompetent children 2–15 years of age.a c (See Atopic Dermatitis under Uses.)


Long-term effects on the developing immune system in infants and children are not known.12 13 14 a


Not recommended for use in immunocompromised children.12 13 14 a


Geriatric Use

No substantial differences in safety relative to younger adults.1


Renal Impairment

Use with caution in patients predisposed to renal impairment.a (See Renal Effects.)


Common Adverse Effects


Burning sensation, pruritus, flu-like symptoms, skin erythema, headache.1 5 6


Interactions for Protopic


No formal drug interaction studies have been performed to date.1


Drugs Affecting Hepatic Microsomal Enzymes


Potential pharmacokinetic interaction with inhibitors of CYP3A4 isoenzyme in patients with widespread and/or erythrodermic disease.1


Specific Drugs
























Drug



Interaction



Comments



Antifungals, azoles



Potential interaction (inhibition of tacrolimus metabolism) in patients with widespread and/or erythrodermic disease (which may increase systemic absorption)1



Caution advised in patients with widespread and/or erythrodermic disease1



Calcium-channel blocking agents



Potential interaction (inhibition of tacrolimus metabolism) in patients with widespread and/or erythrodermic disease (which may increase systemic absorption)1



Caution advised in patients with widespread and/or erythrodermic disease1



Cimetidine



Potential interaction (inhibition of tacrolimus metabolism) in patients with widespread and/or erythrodermic disease (which may increase systemic absorption)1



Caution advised in patients with widespread and/or erythrodermic disease1



Erythromycin



Potential interaction (inhibition of tacrolimus metabolism) in patients with widespread and/or erythrodermic disease (which may increase systemic absorption)1



Caution advised in patients with widespread and/or erythrodermic disease1



Meningococcal vaccine



Responses to meningococcal serogroup C similar in children 2–11 years of age with moderate to severe atopic dermatitis treated with topical tacrolimus (0.03%), those treated with topical hydrocortisone, and in healthy childrena



Pneumococcal 23-valent polysaccharide vaccine



Protective antibody titers achieved in limited number of children 2–12 years of age with moderate to severe atopic dermatitis treated with topical tacrolimus (0.03%)a


Protopic Pharmacokinetics


Absorption


Bioavailability


Minimally absorbed into systemic circulation following topical application to the skin.a Apparent systemic bioavailability approximately 0.5%.a


Systemic absorption decreases as atopic dermatititis resolves.a


Following topical application (53% of total body surface area) in adults, systemic exposure is approximately 30-fold less than following oral administration of immunosuppressive dosages of tacrolimus in adult kidney and liver transplant patients.a


Blood concentrations in children receiving tacrolimus topically occasionally have been in the concentration range achieved with systemic therapy.14 a


Use of occlusive dressing/wrappings or on the face or neck, large areas of the body (i.e., >50% of the total body surface area), or areas of broken skin may increase systemic exposure to the drug.3 11


Distribution


Plasma Protein Binding


Approximately 99% (mainly albumin and α1-acid glycoprotein).a


Elimination


Metabolism


Studies using systemic tacrolimus indicate that the drug is extensively metabolized in the liver and in the GI tract, principally via oxidation by CYP isoenzymes.10 11 a


Elimination Route


Following oral or IV administration, eliminated principally in feces (92%); approximately 1–2% excreted unchanged in urine.a


Half-life


Following IV administration, elimination half-life of approximately 44–48 hours in healthy individuals;a similar elimination half-life (31–48 hours) following oral administration.a


Stability


Storage


Topical


Ointment

15–30°C.1


ActionsActions



  • Exact mechanism(s) of immunosuppressive action in the treatment of atopic dermatitis not known.1




  • Inhibits T-lymphocyte cell activation; shown to inhibit release of mediators from skin mast cells and basophils and to downregulate the expression of high-affinity receptors for immunoglobulin E (IgE) on Langerhans cells.1 2




  • Not genotoxic and does not interact directly with DNA; however, may impair local immunosurveillance.14



Advice to Patients



  • Importance of reading the patient information (medication guide) provided by the manufacturer before initiating therapy and each time the prescription is refilled.a b




  • Importance of informing clinicians of other medical conditions, including Netherton’s syndrome, skin infections (e.g., chicken pox, herpes), or weakened immune system.a b




  • Advise patients that tacrolimus is for external use on affected areas of the skin only.a b Importance of patients or caregivers washing their hands before and after application if hands are not an area for treatment.1




  • Advise patients not to bathe, shower, or swim immediately after application.b




  • Importance of avoiding contact with the eyes.a b




  • Importance of following the clinician’s advice regarding use of other topical preparations; importance of maintaining good skin care practices; apply moisturizers (if used) after tacrolimus.a b




  • Advise patients to discontinue tacrolimus when the signs and symptoms (e.g., itching, rash, redness) of atopic dermatitis (eczema) resolve, or as directed by clinician.a b Importance of following the clinician’s advice if symptoms recur after a course of treatment.a b




  • Importance of not using the drug in children <2 years of age.a




  • Importance of using only the 0.03% ointment in children 2–15 years of age;a b either 0.03% or 0.1% ointment may be used in adults and adolescents ≥16 years of age.a b




  • Importance of avoiding use of bandages, dressings, or wrappings on treated skin.a b




  • Importance of not using the drug for any disorder other than that for which it was prescribed.1




  • Importance of using tacrolimus exactly as prescribed and of not using the drug continuously for a long period of time.a b Importance of using the minimum amount required to control signs and symptoms of atopic dermatitis; importance of using the drug for short-term or intermittent therapy (e.g., courses repeated after treatment-free intervals) only.12 13 a b




  • Importance of reporting persistently swollen glands or any other adverse reactions to clinician.a b




  • Importance of notifying clinician if the signs and symptoms of atopic dermatitis do not improve after 6 weeks of therapy or at any time become noticeably worse.a b




  • Importance of notifying clinician if a skin infection develops during treatment with tacrolimus.a b




  • Importance of avoiding or limiting exposure of unprotected skin to natural or artificial sunlight (tanning beds or UVA/B light) while using tacrolimus ointment (even when the drug is not on the skin); wear protective clothing and use a broad-spectrum sunscreen with a high protection factor.3 11 a b




  • Importance of not swallowing tacrolimus; contact clinician if swallowed.a b




  • Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription or OTC drugs, dietary supplements, herbal supplements, any other skin product, or any form of phototherapy (UVA or UVB).9 a b




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.1




  • Importance of informing patients of other important precautionary information. (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.


















Tacrolimus

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Topical



Ointment



0.03%



Protopic



Astellas



0.1%



Protopic



Astellas


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 04/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Protopic 0.03% Ointment (ASTELLAS): 60/$251.17 or 180/$732.8


Protopic 0.03% Ointment (ASTELLAS): 30/$132.99 or 90/$384.15


Protopic 0.1% Ointment (ASTELLAS): 60/$243.24 or 180/$691.04


Protopic 0.1% Ointment (ASTELLAS): 100/$403.88 or 300/$1168.43


Protopic 0.1% Ointment (ASTELLAS): 30/$124.42 or 90/$359.4



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions July 01, 2006. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.




References



1. Astellas Pharma US, Inc. Protopic (tacrolimus) ointment prescribing information. Deerfield, IL; 2005 Jul.



2. Bekersky I, Fitzsimmons W, Tanase A et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol. 2001; 44(1 Suppl):S17-27. [IDIS 457747] [PubMed 11145792]



3. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting. 54th meeting. Bethesda, MD: Food and Drug Administration; 2000 Nov 16.



4. Hanifin JM, Ling MR, Langley R et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol. 2001; 44(1 Suppl):S28-38.



5. Soter NA, Fleischer AB Jr, Webster GF et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. J Am Acad Dermatol. 2001; 44(1 Suppl):S39-46.



6. Paller A, Eichenfield LF, Leung DY et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol. 2001; 44(1 Suppl):S47-57.



7. Kang S, Lucky AW, Pariser D et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol. 2001; 44(1 Suppl):S58-64. [IDIS 457751] [PubMed 11145796]



8. Reitamo S, Wollenberg A, Schopf E et al for the European Tacrolimus Ointment Study Group. Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol. 2000; 136:999-1006. [IDIS 451208] [PubMed 10926735]



9. Astellas Pharma US, Inc. Protopic (tacrolimus) ointment patient information. Deerfield, IL; 2005 Apr.



10. Fujisawa Healthcare, Inc. Prograf (tacrolimus) for injection and oral capsules prescribing information. Deerfield, IL; 1998 Oct.



11. Reviewers’ comments (personal observations).



12. Anon. FDA issues public health advisory informing health care providers of safety concerns associated with the use of two eczema drugs, Elidel and Protopic. FDA Talk Paper. Rockville, MD: Food and Drug Administration; 2005 March 10. From the FDA website: . Accessed on May 25, 2005.



13. Food and Drug Administration (FDA). FDA Public Health Advisory regarding potential cancer risk from use of Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment. From FDA website: . 2005 Mar 10. Accessed on May 25, 2005.



14. Food and Drug Administration (FDA). FDA alert for healthcare professionals regarding potential cancer risk from use of tacrolimus (marketed as Protopic). From FDA website: . Accessed on May 25, 2005.



a. Astellas Pharma US, Inc. Protopic (tacrolimus) ointment 0.03 and 0.1% prescribing information. Deerfield, IL; 2006 Jan.



b. Astellas Pharma US, Inc. Protopic (tacrolimus) ointment 0.03 and 0.1% medication guide. Deerfield, IL; 2006 Jan.



c. Rico MJ. Dear health care provider letter regarding important safety information regarding Protopic and rare cases of malignancy reported in patients treated with topical calcineurin inhibitors. Deerfield, IL; 2006 Jan 19.



More Protopic topical resources


  • Protopic topical Side Effects (in more detail)
  • Protopic topical Use in Pregnancy & Breastfeeding
  • Protopic topical Support Group
  • 6 Reviews for Protopic - Add your own review/rating


Compare Protopic topical with other medications


  • Atopic Dermatitis
  • Perioral Dermatitis

Cortisporin Cream


Cortisporin Cream is a brand name of hydrocortisone/neomycin/polymyxin b topical, approved by the FDA in the following formulation(s):


CORTISPORIN (hydrocortisone acetate; neomycin sulfate; polymyxin b sulfate - cream; topical)



  • Manufacturer: MONARCH PHARMS

    Approval date: August 9, 1985

    Strength(s): 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM [RLD]

Has a generic version of Cortisporin Cream been approved?


No. There is currently no therapeutically equivalent version of Cortisporin Cream available.


Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Cortisporin Cream. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.




Related Patents

There are no current U.S. patents associated with Cortisporin Cream.

See also...

  • Cortisporin Cream Consumer Information (Wolters Kluwer)
  • Hydrocortisone/Neomycin/Polymyxin B Cream Consumer Information (Wolters Kluwer)

Psorcon E


Generic Name: diflorasone (Topical application route)


dye-FLOR-a-sone dye-AS-e-tate


Commonly used brand name(s)

In the U.S.


  • Apexicon

  • Apexicon E

  • Maxiflor

  • Psorcon

  • Psorcon E

In Canada


  • Florone

  • Flutone

Available Dosage Forms:


  • Ointment

  • Cream

Therapeutic Class: Corticosteroid, Strong


Pharmacologic Class: Diflorasone


Uses For Psorcon E


Diflorasone topical is used to help relieve redness, itching, swelling, or other discomfort caused by skin conditions. This medicine is a corticosteroid (cortisone-like medicine or steroid).


This medicine is available only with your doctor's prescription.


Before Using Psorcon E


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies performed to date have not demonstrated pediatric-specific problems that would limit the usefulness of diflorasone topical in the pediatric population. However, because of this medicine's toxicity, it should be used with caution. Children may absorb large amounts through the skin, which can cause serious side effects. If your child is using this medicine, follow your doctor's instructions very carefully. For the cream form, safety and efficacy have not been established.


Geriatric


No information is available on the relationship of age to the effects of diflorasone topical in geriatric patients.


Pregnancy








Pregnancy CategoryExplanation
All TrimestersCAnimal studies have shown an adverse effect and there are no adequate studies in pregnant women OR no animal studies have been conducted and there are no adequate studies in pregnant women.

Breast Feeding


There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. Tell your healthcare professional if you are taking any other prescription or nonprescription (over-the-counter [OTC]) medicine.


Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Cushing's syndrome (adrenal gland disorder) or

  • Diabetes or

  • Hyperglycemia (high blood sugar) or

  • Intracranial hypertension (increased pressure in the head)—Use with caution. May make these conditions worse.

  • Infection of the skin at or near the place of application or

  • Large sores, broken skin, or severe skin injury at the place of application—The chance of side effects may be increased.

  • Perioral dermatitis (skin problem) or

  • Rosacea (skin problem)—The cream should not be used in patients with these conditions.

Proper Use of diflorasone

This section provides information on the proper use of a number of products that contain diflorasone. It may not be specific to Psorcon E. Please read with care.


It is very important that you use this medicine only as directed by your doctor. Do not use more of it, do not use it more often, and do not use it for a longer time than your doctor ordered. To do so may cause unwanted side effects or skin irritation.


This medicine is for use on the skin only. Do not get it in your eyes. Do not use it on skin areas that have cuts, scrapes, or burns. If it does get on these areas, rinse it off right away with water.


This medicine should only be used for skin conditions that your doctor is treating. Check with your doctor before using it for other conditions, especially if you think that a skin infection may be present. This medicine should not be used to treat certain kinds of skin infections or conditions, such as severe burns.


Do not use the topical cream on the face, groin, or underarms unless directed to do so by your doctor.


To use:


  • Wash your hands with soap and water before and after using this medicine.

  • Apply a thin layer of this medicine to the affected area of the skin. Rub it in gently.

  • Do not bandage or otherwise wrap the skin being treated unless directed to do so by your doctor.

  • If the medicine is applied to the diaper area of an infant, do not use tight-fitting diapers or plastic pants unless directed to do so by your doctor.

  • If your doctor ordered an occlusive dressing or airtight covering to be applied over the medicine, make sure you know how to apply it. Occlusive dressings increase the amount of medicine absorbed through your skin, so use them only as directed. If you have any questions about this, check with your doctor.

Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For redness, itching, and swelling of the skin:
    • For topical dosage form (cream):
      • Adults—Apply to the affected area of the skin two times per day.

      • Children—Use and dose must be determined by your doctor.


    • For topical dosage form (ointment):
      • Adults—Apply to the affected area of the skin one to three times per day.

      • Children—Apply to the affected area of the skin one to three times per day.



Missed Dose


If you miss a dose of this medicine, apply it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Precautions While Using Psorcon E


It is very important that your doctor check the progress of you or your child at regular visits for any unwanted effects that may be caused by this medicine.


If your or your child's symptoms do not improve within a few days, or if they become worse, check with your doctor.


Using too much of this medicine or using it for a long time may increase your risk of having adrenal gland problems. The risk is greater for children and patients who use large amounts for a long time. Talk to your doctor right away if you or your child have more than one of these symptoms while you are using this medicine: blurred vision; dizziness or fainting; a fast, irregular, or pounding heartbeat; increased thirst or urination; irritability; or unusual tiredness or weakness.


Stop using this medicine and check with your doctor right away if you or your child have a skin rash, burning, stinging, swelling, or irritation on the skin.


Do not use cosmetics or other skin care products on the treated areas.


Psorcon E Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Incidence not known
  • Blistering, burning, crusting, dryness, or flaking of the skin

  • irritation

  • itching, scaling, severe redness, soreness, or swelling of the skin

  • redness and scaling around the mouth

  • thinning of the skin with easy bruising, especially when used on the face or where the skin folds together (e.g. between the fingers)

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


Incidence not known
  • Acne or pimples

  • burning and itching of the skin with pinhead-sized red blisters

  • burning, itching, and pain in hairy areas, or pus at the root of the hair

  • increased hair growth on the forehead, back, arms, and legs

  • lightening of normal skin color

  • lightening of treated areas of dark skin

  • reddish purple lines on the arms, face, legs, trunk, or groin

  • softening of the skin

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Psorcon E resources


  • Psorcon E Use in Pregnancy & Breastfeeding
  • Psorcon E Drug Interactions
  • Psorcon E Support Group
  • 0 Reviews for Psorcon E - Add your own review/rating


  • Psorcon E Concise Consumer Information (Cerner Multum)

  • Apexicon Cream MedFacts Consumer Leaflet (Wolters Kluwer)

  • Apexicon Prescribing Information (FDA)

  • Apexicon E Prescribing Information (FDA)

  • Florone Prescribing Information (FDA)

  • Psorcon Monograph (AHFS DI)

  • psorcon Prescribing Information (FDA)



Compare Psorcon E with other medications


  • Atopic Dermatitis
  • Eczema
  • Psoriasis
  • Skin Rash
  • Urticaria